Cargando…

Pulmonary vasodilator therapy in sarcoidosis‐associated pulmonary hypertension may decrease lung function decline and mortality

The efficacy of treating sarcoidosis‐associated pulmonary hypertension (SAPH) with pulmonary vasodilator therapy is unclear. The INCREASE trial showed improvement in 6‐minute walk distance (6MWD) and in decline in functional vital capacity (FVC) in patients with interstitial lung disease and pulmona...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gayen, Shameek, Ansari, Sohaib, Lashari, Bilal H., Zhao, Huaqing, Criner, Gerard J., Gupta, Rohit, James Mamary, Albert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10241350/ https://www.ncbi.nlm.nih.gov/pubmed/37284520 http://dx.doi.org/10.1002/pul2.12245

Ejemplares similares

Predictors of hospitalization for respiratory failure among patients with sarcoidosis‐associated pulmonary hypertension
por: Gayen, Shameek, et al.
Publicado: (2023)

Sarcoidosis lung transplantation waitlist mortality, a national registry database study
por: Fleitas Sosa, Derlis C., et al.
Publicado: (2023)

Nasopharyngolaryngoscopy as a Triage Tool for Airway Compromise in Angioedema: A Retrospective Cohort Study
por: Gayen, Shameek, et al.
Publicado: (2022)

Pulmonary hemodynamics and transplant‐free survival in sarcoidosis‐associated pulmonary hypertension: Results from an international registry
por: Gayen, Shameek K., et al.
Publicado: (2023)

Pulmonary vasculopathy in explanted lungs from patients with interstitial lung disease undergoing lung transplantation
por: Dotan, Yaniv, et al.
Publicado: (2020)

Effectiveness of pulmonary vasodilators on pulmonary hypertension associated with POEMS syndrome
por: Ohashi, Kana, et al.
Publicado: (2019)

Clinical predictors and explant lung pathology of acute exacerbation of idiopathic pulmonary fibrosis
por: Dotan, Yaniv, et al.
Publicado: (2020)

Adenosine as pulmonary vasodilator in ARDS
por: Molina, JM, et al.
Publicado: (1998)

Pulmonary hypertension complicating pulmonary sarcoidosis
por: Huitema, M. P., et al.
Publicado: (2016)

Oxygen-Sensitivity and Pulmonary Selectivity of Vasodilators as Potential Drugs for Pulmonary Hypertension
por: Morales-Cano, Daniel, et al.
Publicado: (2021)

Improvement of pulmonary arterial compliance by pulmonary vasodilator in pulmonary hypertension from combined pulmonary fibrosis and emphysema
por: Kusaka, Kei, et al.
Publicado: (2019)

Unexpected pulmonary mechanics during positive pressure mechanical ventilation in fibrotic lung disease with concomitant flail chest
por: Gayen, Shameek, et al.
Publicado: (2022)

Inhaled pulmonary vasodilators in refractory hypoxemia
por: Wright, Brian J.
Publicado: (2015)

Effects of Different Pulmonary Vasodilators on Arterial Saturation in a Model of Pulmonary Hypertension
por: Becker, Eva Maria, et al.
Publicado: (2013)

Pulmonary vasodilators: beyond the bounds of pulmonary arterial hypertension therapy in COVID-19
por: Franco, Veronica, et al.
Publicado: (2020)

Pulmonary hypertension associated with sarcoidosis
por: Baughman, Robert P
Publicado: (2007)

Pulmonary vasodilation in acute pulmonary embolism – a systematic review
por: Lyhne, Mads Dam, et al.
Publicado: (2020)

Pulmonary Function in Pulmonary Sarcoidosis
por: Yao, Qian, et al.
Publicado: (2023)

Management of pulmonary vasodilator therapy in patients with pulmonary arterial hypertension during critical illness
por: Muzevich, Katie M, et al.
Publicado: (2014)

Sarcoidosis Presenting as Acute Respiratory Distress Syndrome
por: Lashari, Bilal Haider, et al.
Publicado: (2018)

Why Pulmonary Vasodilation May Be Part of a Key Strategy to Improve Survival in COVID-19
por: Solaimanzadeh, Isaac
Publicado: (2021)

Efficacy and safety of oral pulmonary vasodilators in pulmonary veno‐occlusive disease
por: Nakamura, Junichi, et al.
Publicado: (2022)

Pulmonary and extra-pulmonary manifestations of sarcoidosis
por: Tavana, Sasan, et al.
Publicado: (2015)

Dramatic and sustained responsiveness of pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension to vasodilator therapy
por: May, Adam, et al.
Publicado: (2014)

Editorial: Pulmonary sarcoidosis
por: Dhooria, Sahajal, et al.
Publicado: (2023)

Pulmonary fibrosis in sarcoidosis
por: Asif, Huda, et al.
Publicado: (2023)

The Symptoms of Pulmonary Sarcoidosis
por: Judson, Marc A.
Publicado: (2023)

Pulmonary Hypertension Associated Genetic Variants in Sarcoidosis Associated Pulmonary Hypertension
por: Groen, Karlijn, et al.
Publicado: (2022)

Acute vasodilator testing: An opportunity to advance the precision care of pulmonary hypertension
por: Cirulis, Meghan M., et al.
Publicado: (2019)

Coexistence of pulmonary tuberculosis with pulmonary sarcoidosis and skin sarcoidosis: a case report
por: Yusuf, Khalifa Abdulrahman, et al.
Publicado: (2023)

It’s Time to Put the Term “Pulmonary Vasodilators” to Rest
por: Rubin, Lewis J.
Publicado: (2021)

Selective Use of Pulmonary Vasodilators in Patients with Fontan Physiology
por: Glenn, Thomas, et al.
Publicado: (2022)

Pulmonary vasodilators can lead to various complications in pulmonary “arterial” hypertension associated with congenital heart disease
por: Chida-Nagai, Ayako, et al.
Publicado: (2020)

Outcomes of pulmonary vasodilator use in Veterans with pulmonary hypertension associated with left heart disease and lung disease
por: Gillmeyer, Kari R., et al.
Publicado: (2021)

The Efficacy and Safety of Pulmonary Vasodilators in Pediatric Pulmonary Hypertension (PH): A Systematic Review and Meta-analysis
por: Shu, Tingting, et al.
Publicado: (2021)

Children with Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension Treated with Pulmonary Vasodilators—The Pediatric Cardiologist Point of View
por: Migdał, Anna, et al.
Publicado: (2021)

Beneficial Effects of Pulmonary Vasodilators on Pre-Capillary Pulmonary Hypertension in Patients with Chronic Kidney Disease on Hemodialysis
por: Kimuro, Keiji, et al.
Publicado: (2022)

WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension
por: Savale, Laurent, et al.
Publicado: (2022)

Predictive value of pulmonary function testing in the evaluation of pulmonary hypertension in sarcoidosis
por: Jose, Arun, et al.
Publicado: (2018)

Comparison of Balloon Pulmonary Angioplasty and Pulmonary Vasodilators for Inoperable Chronic Thromboembolic Pulmonary Hypertension: A Systematic Review and Meta-Analysis
por: Kalra, Rajat, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e2lqi74m64s45e9jgop2fje4s7